Ardent Health (ARDT) Q4 2025 earnings summary

Executive summary

• Achieved record-high full-year 2025 revenue of $6.32 billion (6% growth) and adjusted EBITDA of $545 million (9.3% growth), with margin expansion of 20 basis points to 8.6%.

• Q4 2025 revenue was $1.61 billion, nearly flat year-over-year, and adjusted EBITDA was $134 million, down 26.6% due to prior year state payment program benefits.

• Operating cash flow for 2025 reached $471 million, up 49% from 2024, with cash and equivalents rising to $710 million at year-end.

• IMPACT program initiatives delivered significant cost savings, especially in contract labor, and are expected to generate $55 million in 2026.

• Technology and AI deployment, including virtual care and AI scribe tools, are enhancing efficiency, care quality, and revenue capture.

Financial highlights

• FY25 total revenue: $6.32 billion (6% YoY growth); Q4 revenue: $1.61 billion (flat YoY, up 3% adjusted for prior year DPP benefit).

• FY25 adjusted EBITDA: $545 million (9.3% YoY growth); Q4 adjusted EBITDA: $134 million (-26.6% YoY).

• Operating cash flow for FY25: $471 million (+49% YoY); free cash flow net of non-controlling interest distributions: $170 million.

• Lease-adjusted net leverage improved to 2.5x from 2.9x; cash and cash equivalents at year-end 2025 were $710 million.

• Net income attributable to shareholders for FY25 was $135.8 million, down from $210.3 million in 2024.

Outlook and guidance

• 2026 revenue guidance: $6.4–$6.7 billion; adjusted EBITDA guidance: $485–$535 million; net income: $129–$183 million.

• Adjusted admissions growth expected at 1.5–2.5% for 2026, factoring in exchange disruption from subsidy expirations.

• IMPACT program savings target raised to $55 million for 2026, up from $40 million.

• Capital expenditures projected at $225–$265 million for 2026.

• Guidance reflects headwinds from professional fee pressures, payor denials, and expiration of enhanced Exchange subsidies, offset by IMPACT program savings.